Cargando…

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95...

Descripción completa

Detalles Bibliográficos
Autores principales: Risso, Vesna, Lafont, Elodie, Le Gallo, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931059/
https://www.ncbi.nlm.nih.gov/pubmed/35301281
http://dx.doi.org/10.1038/s41419-022-04688-x
_version_ 1784671173978619904
author Risso, Vesna
Lafont, Elodie
Le Gallo, Matthieu
author_facet Risso, Vesna
Lafont, Elodie
Le Gallo, Matthieu
author_sort Risso, Vesna
collection PubMed
description Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95L pathway have been involved in several disease conditions ranging from autoimmune diseases to inflammation and cancer. CD95L-induced cell death has multiple roles in the immune response since it constitutes one of the mechanisms by which cytotoxic lymphocytes kill their targets, but it is also involved in the process of turning off the immune response. Furthermore, beyond the canonical pro-death signals, CD95L, which can be membrane-bound or soluble, also induces non-apoptotic signaling that contributes to its tumor-promoting and pro-inflammatory roles. The intent of this review is to describe the role of CD95/CD95L in the pathophysiology of cancers, autoimmune diseases and chronic inflammation and to discuss recently patented and emerging therapeutic strategies that exploit/block the CD95/CD95L system in these diseases.
format Online
Article
Text
id pubmed-8931059
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89310592022-04-01 Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases Risso, Vesna Lafont, Elodie Le Gallo, Matthieu Cell Death Dis Review Article Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95L pathway have been involved in several disease conditions ranging from autoimmune diseases to inflammation and cancer. CD95L-induced cell death has multiple roles in the immune response since it constitutes one of the mechanisms by which cytotoxic lymphocytes kill their targets, but it is also involved in the process of turning off the immune response. Furthermore, beyond the canonical pro-death signals, CD95L, which can be membrane-bound or soluble, also induces non-apoptotic signaling that contributes to its tumor-promoting and pro-inflammatory roles. The intent of this review is to describe the role of CD95/CD95L in the pathophysiology of cancers, autoimmune diseases and chronic inflammation and to discuss recently patented and emerging therapeutic strategies that exploit/block the CD95/CD95L system in these diseases. Nature Publishing Group UK 2022-03-17 /pmc/articles/PMC8931059/ /pubmed/35301281 http://dx.doi.org/10.1038/s41419-022-04688-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Risso, Vesna
Lafont, Elodie
Le Gallo, Matthieu
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title_full Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title_fullStr Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title_full_unstemmed Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title_short Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
title_sort therapeutic approaches targeting cd95l/cd95 signaling in cancer and autoimmune diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931059/
https://www.ncbi.nlm.nih.gov/pubmed/35301281
http://dx.doi.org/10.1038/s41419-022-04688-x
work_keys_str_mv AT rissovesna therapeuticapproachestargetingcd95lcd95signalingincancerandautoimmunediseases
AT lafontelodie therapeuticapproachestargetingcd95lcd95signalingincancerandautoimmunediseases
AT legallomatthieu therapeuticapproachestargetingcd95lcd95signalingincancerandautoimmunediseases